Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006052 · ClinicalTrials.gov registry record · Phase 2
STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006052: Completed Phase 2 study, sponsored by Novartis.
NCT00006052 is a Phase 2 study that has completed, run by Novartis. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006052, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have accelerated phase chronic myelogenous leukemia.
Interventions
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Phase | Phase 2 |
What the finished NCT00006052 record still lists
NCT00006052 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which imatinib mesylate is the first listed.
NCT00006052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006052 about?
NCT00006052 is a clinical study titled "STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia". RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have accelerated phase chronic myelogenous leukemia.
What is the current status of trial NCT00006052?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06.
What interventions are being tested in trial NCT00006052?
The interventions under investigation include: imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00006052?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia